Real-World Use of Novel Treatments in Patients With Spinal Muscular Atrophy (SMA): A Multi-Site Retrospective Chart Review of Pediatric SMA Patients Outside of the United States
Completed
- Conditions
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 162
- Registration Number
- NCT06178393
- Locations
- 🇺🇸
Novartis, Bannockburn, Illinois, United States
Incidence of Psoriatic Arthritis Among Psoriasis Patients Newly Initiated With Secukinumab in a US Claims Database and a UK Registry
Completed
- Conditions
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1171
- Registration Number
- NCT06172426
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Treatment Patterns and Real-World Clinical Outcomes in Patients With Advanced NSCLC and MET Exon 14 Skipping Mutation in the United States
Completed
- Conditions
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 287
- Registration Number
- NCT06161051
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Kesimpta Pregnancy and Infant Safety Study Using Real World Data
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1500
- Registration Number
- NCT06156683
- Locations
- 🇨🇭
Novartis Investigative Site, Basel, Switzerland
Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 294
- Registration Number
- NCT06157086
- Locations
- 🇫🇷
Novartis Investigative Site, Valence Cedex 9, France
Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)
- First Posted Date
- 2023-12-04
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 5
- Registration Number
- NCT06155500
- Locations
- 🇺🇸
St Jude Childrens Rsrch Hospital, Memphis, Tennessee, United States
A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT06149104
- Locations
- 🇯🇵
Novartis Investigative Site, Toyama, Japan
A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the Russia
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 376
- Registration Number
- NCT06148506
- Locations
- 🇷🇺
Novartis Investigative Site, Yaroslavl, Russian Federation
Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database
Completed
- Conditions
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 425
- Registration Number
- NCT06148493
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT06142357
- Locations
- 🇷🇺
Novartis Investigative Site, Yakutsk, Russian Federation
© Copyright 2024. All Rights Reserved by MedPath